Preliminary results of active surveillance in localized prostate cancer GG1

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Active surveillance is a widely used treatment for clinically localized low-risk prostate cancer in the Western countries; however, its safety and efficacy in the Belarussian healthcare settings have not been established.

Aim. To evaluate the short-term outcomes of active surveillance in our cohort and to analyze predictive factors for reclassification.

Materials and methods. The study included 249 patients with verified clinically localized prostate cancer, a life expectancy of ≥10 years, and at least one surveillance biopsy. The primary endpoint was survival (time) to reclassification (increased differentiation group or increased clinical stage). Various predictive factors for reclassification were also analyzed.

Results. Median follow-up was 31.2 months (95 % confidence interval 28.2–34.1 months). Tumor reclassification occurred in 62 cases (24.9 %). Median time to reclassification was 65.2 months, and to treatment, 55 months. According to multivariate analysis, prostate-specific antigen density (p <0.001) and percentage of positive cores in biopsy (p = 0.006) were the most significant predictors of reclassification.

Conclusion. The method demonstrated acceptable safety and efficacy results; however, continued follow-up is necessary to determine long-term outcomes.

About the authors

Aliaksandr M. Pozharytski

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Author for correspondence.
Email: pozarickii.a.m@gmail.com
ORCID iD: 0009-0006-6620-2088
Belarus, 2 Lesnoy Minsk District 223040

Yu. A. Poddubny

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
Belarus, 2 Lesnoy Minsk District 223040

M. L. Parmon

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
Belarus, 2 Lesnoy Minsk District 223040

L. N. Suslov

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
ORCID iD: 0009-0006-3712-8405
Belarus, 2 Lesnoy Minsk District 223040

A. N. Ryabcheuski

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
Belarus, 2 Lesnoy Minsk District 223040

S. L. Polyakov

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
ORCID iD: 0000-0003-1591-6313
Belarus, 2 Lesnoy Minsk District 223040

S. A. Krasny

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
ORCID iD: 0000-0003-3244-5664
Belarus, 2 Lesnoy Minsk District 223040

A. I. Rolevich

N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology

Email: pozarickii.a.m@gmail.com
ORCID iD: 0000-0002-9811-6591
Belarus, 2 Lesnoy Minsk District 223040

References

  1. Hamdy F., Donovan J., Lane J. et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388:1547–58. doi: 10.1056/NEJMoa2208275
  2. Bastian P., Mangold L., Epstein J. et al. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101(9):2001–5. doi: 10.1002/cncr.20586
  3. Iremashvili V., Soloway M., Rosenberg D. et al. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 2012;187:1594–9. doi: 10.1016/j.juro.2011.12.082
  4. Shappley W., Kenfield S., Kasperzyk J. et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980–5. doi: 10.1200/JCO.2008.21.2613
  5. Valeri A., Papin G., Moineau M. et al. Is screen-detected prostate cancer in high risk families eligible for active surveillance? Eur Urol Suppl 2010;9:196.
  6. Sundi D., Kryvenko O., Epstein J. et al. Reclassification rates are higher among African American men than white men on active surveillance. J Urol Suppl 2014;191:598–9. doi: 10.1016/j.urology.2014.08.014
  7. Klotz L., Zhang L., Lam A. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31. doi: 10.1200/JCO.2009.24.2180
  8. Van den Bergh R., Vasarainen H., van der Poel H. et al. Shortterm outcomes of the prospective multicentre ‘‘Prostate Cancer Research International: Active Surveillance’’ study. BJU Int 2010;105:956–62. doi: 10.1111/j.1464-410X.2009.08887.x
  9. Smith A., Coward M., Doak H. et al. Outcomes and implications of follow-up biopsies of men on active surveillance for low-risk prostate cancer. J Urol Suppl 2009;181:608.
  10. Umbehr M., Platz E., Peskoe et al. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. BJU Int 2014;113:561–7. doi: 10.1111/bju.12131
  11. Ross A., Loeb S., Landis P. et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810–6. doi: 10.1200/JCO.2009.25.7311
  12. Barayan G., Brimo F., Bégin L. et al. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU Int 2014;114:99–104. doi: 10.1111/bju.12754
  13. Davis J., Ward J., Pettaway C. et al. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 2015;118(1):68–76. doi: 10.1111/bju.13193
  14. Iremashvili V., Burdick-Will J., Soloway M. et al. Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. BJU Int 2013;112:39–44. doi: 10.1111/bju.12112
  15. Tosoian J., Mamawala M., Epstein J. et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015;33(30):3379–85. doi: 10.1200/JCO.2015.62.5764
  16. San Francisco I., Werner L., Regan M. et al. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011;185:471–6. doi: 10.1016/j.juro.2010.09.115
  17. Kotb A., Tanguay S., Luz M. et al. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 2010;14:53–7. doi: 10.1038/pcan.2010.36
  18. Bul M., Zhu X., Valdagni R. et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013;63:597–603. doi: 10.1016/j.eururo.2012.11.005
  19. Klotz L., Vesprini D., Sethukavalan P. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272–7. doi: 10.1200/JCO.2014.55.1192
  20. Petrelli F., Vavassori I., Cabiddu M. et al. Predictive factors for reclassification and relapse in prostate cancer eligible for active surveillance: a systematic review and meta-analysis. Urology 2016;16:127–38. doi: 10.1016/j.urology.2016.01.034

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.